EICHORCondition: Cellulite · Sponsor: Caliway Biopharmaceuticals Co., Ltd.
The Stage 2 of this phase 2 study is an open-label, single-arm study to assess the efficacy and safety of CBL-514 in participants with Edematous Fibrosclerotic Panniculopathy (EFP) cellulite.
This description comes directly from the study's public registry record.
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
| Investigational Site 6 | Encinitas, California, United States | — |
| Investigational Site 1 | Encino, California, United States | — |
| Investigational Site 3 | San Diego, California, United States | — |
| Investigational Site 4 | Coral Gables, Florida, United States | — |
| Investigational Site 2 | New York, New York, United States | — |
Sponsor or site team? See the site landscape for this trial — listed sites, countries, and recruiting-density context.
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05836779